Background: The aim of this study was to look into our experience of resection for hepatocellular carcinomas (HCCs) in a tertiary Hepatobiliary and Liver Transplant Unit in the UK. Methods: A retrospective analysis of our prospective database was carried out. Results: 715 cases of HCC were seen. 100 (13.9%) underwent hepatic resection and 159 (22.2%) orthotopic liver transplant. The 1-, 3- and 5-year overall survival following resection was 75.3, 37.0 and 21.5% respectively. Factors affecting long-term survival included resection margin (p < 0.001), recurrence (p < 0.007), α-fetoprotein >50 (p < 0.001) and serum albumin (p < 0.03). On multivariate analysis, recurrence (p < 0.001) and histological grade (p < 0.044) were significant. The 1- and 3-year recurrence rates were 27.3 and 72.5% respectively. Histological grade (p < 0.007), α-fetoprotein >50 (p < 0.033), female gender (p < 0.016) and portal vein involvement (p < 0.016) were significant in recurrence. Conclusions: Resection data from the East may not be comparable to the West owing to the higher transplant activity in the latter. Liver function tests and imaging would be sufficient to assess liver function prior to hepatic resection. HCC with cirrhosis should be assessed by a transplant unit prior to any treatment. The MELD (Model for End-Stage Liver Disease) score would be a valuable preoperative tool in the assessment of cirrhotics.

1.
Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: GLOBOCAN 2000. Int J Cancer 2001;94:153–156.
2.
Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al: Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463–472.
3.
Fong ST, Lai EC, Lo CM, NG IO, Wong J: Hospital mortality of major hepatectomy for hepatocellular carcinoma associated with cirrhosis. Arch Surg 1995;130:198–203.
4.
Ryder SD: Guidelines for the diagnosis and treatment of hepatocellular carcinoma in adults. Gut 2003;52(suppl 3):1–8.
5.
Wingo PA, Tong T, Bolden S: Cancer Statistics, 1995. Ca Cancer J Clin 1995;45:8–30.
6.
Di Bisceglie AM: Hepatitis C and hepatocellular carcinoma. Semin Liver Dis 1995;15:64–69.
7.
Beasley RP: Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer 1988;61:1942–1956.
8.
França AVC, Elias J Jr, Lima BLG, Martinelli ALC, Carrilho FJ: Diagnosis, staging and treatment of hepatocellular carcinoma. Braz J Med Biol Res 2004;37:1689–1705.
9.
Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K: Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918–928.
10.
Okuda K: Clinical presentation and natural history of hepatocellular carcinoma and other liver cancers; in Okuda K, Tabor E (eds): Liver Cancer. New York, Churchill Livingstone, 1997, pp 1–12.
11.
Kew MC: Hepatic tumours and cysts; in Feldmann M, Sleisenger MH, Scharschmidt BF (eds): Sleisenger Fordtran’s Gastrointestinal and Liver Disease: Pathology/Diagnosis/Management, ed 6. Philadelphia, Saunders, 1998, vol 1, pp 1364–1387.
12.
Fong Y, Sun RL, Jarnagin W, Blumgart LH: An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 1999;229:790–800.
13.
Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693–699.
14.
Calvet X, Bruix J, Bru C, Gines P, Vilana R, Sole M, et al: Natural history of hepatocellular carcinoma in Spain. Five year’s experience in 249 cases. J Hepatol 1990;10:311–317.
15.
Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso M del C, Sala M, et al: Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999;29:62–67.
16.
Wildi S, Pestalozzi B, McCormack L, Clavien P: A. Critical evaluation of the different staging systems for hepatocellular carcinoma. Br J Surg 2004;91:400–408.
17.
Ringe B, Pichlmayr R, Wittekind C, Tusch G: Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 1991;15:270–285.
18.
Iwatsuki S, Starzl TE, Sheahan DG, Yokoyama I, Demetris AJ, Todo S, Tzakis AG, Van Thiel DH, Carr B, Selby R: Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991;214:221–229.
19.
Fuster J, Garcia-Valdecasas JC, Grande L, Tabet J, Bruix J, Anglada T, et al: Hepatocellular carcinoma and cirrhosis. Results of surgical treatment in a European series. Ann Surg 1996;223:297–302.
20.
Ringe B, Pichlmayr R, Wittekind C, Tusch G: Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 1991;15:270–285.
21.
Suenaga M, Nakao A, Harada A, et al: Hepatic resection for hepatocellular carcinoma. World J Surg 1992;16:97–105.
22.
Sasaki Y, Imaoka S, Msutani S, et al: Influence of coexisting cirrhosis on long-term prognosis after surgery in patients with hepatocellular carcinoma. Surgery 1992;112:515–521.
23.
Teh SH, Christein J, Donahue J, Que F, Kendrick M, Farnell M, Cha S, Kamath P, Kim R, Nagorney DM: Hepatic resection of hepatocellular carcinoma in patients with cirrhosis; Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality. J Gastrointest Surg 2005;9:1207–1215.
24.
Friedman LS, Martin P, Santiago JM: Liver function tests and the objective evaluation of the patient with Liver disease; in Zakim D, Boyer TD (eds): Hepatology. Philadelphia, Saunders, 1996, pp 791–883.
25.
Fuster J, Garcia-Valdecasas JC, et al: Hepatocellular carcinoma and cirrhosis. Results of surgical treatment in a European series. Ann Surg 1996;223:297–302.
26.
Kubota K, Makuuchi M, Kusaka K, Kobayashi T, Miki K, Hasegawa K, et al: Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology 1997;26:1176–1181.
27.
Stuart KE, Anand AJ, Jenkins RL: Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer 1996;77:2217–2222.
28.
Livraghi T, Sangalli G, Giordano F, Ravetto C, Solbiati L, Fornari F, et al: 240 hepatocellular carcinomas: ultrasound features, tumor size, cytologic and histologic patterns, serum α-fetoprotein and HBsAg. Tumori 1987;73:507–512.
29.
Chen DS, Sung JL: Serum α-fetoprotein in hepatocellular carcinoma. Cancer 1977;40:779–783.
30.
Bilimoria MM, Lauwers GY, Doherty DA, Nagorney DM, Belghiti J, Do KA, et al: Underlying liver disease, not tumor factors, predicts long-term survival after resection of hepatocellular carcinoma. Arch Surg 2001;136:528–535.
31.
Ouchi K, Sugawara T, Fujiya T, Kamiyama Y, Kakugawa Y, Mikuni J, et al: Prediction of recurrence and extratumor spread of hepatocellular carcinoma following resection. J Surg Oncol 2000;75:241–245.
32.
Llovet JM, Fuster J, Bruix J: Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;30:1434–1440.
33.
Kakar S, Burgart LJ, Batts KP, Garcia J, Jain D, Ferrell LD: Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis. Mod Pathol 2005;18:1417–1423.
34.
Martinez Isla A, Ferrara A, Badia JM, Holloway I, Tanaka H, Riaz A, et al: Fibrolamellar hepatocellular carcinoma: results of partial liver resection. Rev Esp Enferm Dig 1997;89:699–705.
35.
Denis J, Grippon P, Legendre C, Tubiana JM, Levy VG: Fibrolamellar carcinoma of the liver: hepatocellular carcinoma with favourable prognosis. Gastroenterol Clin Biol 1984;8:920–924.
36.
Pinna AD, Iwatsuki S, Lee RG, Todo S, Madariaga JR, Marsh JW, et al: Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation. Hepatology 1997;26:877–883.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.